Nabriva Therapeutics plc announced that it has acquired Zavante Therapeutics. Upon closing of the acquisition, Mr. Ted Schroeder was appointed as chief executive officer of Nabriva Therapeutics to succeed Dr. Broom, and Mr. Schroeder's employment agreement with Nabriva Therapeutics provides that he will be appointed to Nabriva Therapeutics' board of directors effective immediately following Nabriva Therapeutics' 2018 Annual General Meeting of Shareholders, scheduled to be held on August 1, 2018. Dr. Broom will continue to serve on Nabriva Therapeutics' board of directors and will work closely with Mr. Schroeder and the management team as a consultant.

Prior to serving as president, CEO, founder and director of Zavante Therapeutics, Mr. Schroeder co-founded Cadence Pharmaceuticals and served as president, CEO and a member of the board of directors until the company's acquisition by Mallinckrodt Pharmaceuticals in 2014. He had also held several roles at Elan Pharmaceuticals including senior vice president of North American sales and marketing, and vice president and general manager of the hospital products business unit – a role he also held at Dura Pharmaceuticals before its acquisition by Elan. Earlier in his career, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb.

He currently serves on the board of Cidara Therapeutics, Otonomy and Collegium Pharmaceutical. Upon closing of the acquisition, Dr. Steven Gelone, Nabriva's Chief Scientific Officer and Vice President, Business & Corporate Development, has been named President and Chief Operating Officer of Nabriva, reporting to Mr. Schroeder. Along with his current responsibilities, Dr. Gelone will oversee Nabriva's Technical Operations and Quality organizations.

Dr. Gelone joined Nabriva in December 2014.